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bjectives We designed a randomized trial exploiting optical coherence tomography (OCT) to as-
ess coverage and apposition of overlapping bare-metal stents (BMS) and drug-eluting stents (DES)
n human coronary arteries.
ackground Overlapping DES impair healing in animals. Optical coherence tomography allows ac-
urate in vivo assessment of stent strut coverage and apposition.
ethods Seventy-seven patients with long coronary stenoses were randomized to overlapping
irolimus-eluting stents (SES), paclitaxel-eluting stents (PES), zotarolimus-eluting stents (ZES), or BMS.
he primary goal of the study was to determine the rate of uncovered/malapposed struts in overlap
ersus nonoverlap segments, according to stent type, at 6-month follow-up with OCT.
esults A total of 53,047 struts were analyzed. The rate of uncovered/malapposed struts was 1.5 
.4% and 0.6  2.7% in overlap versus nonoverlap BMS (p  NS), respectively, and 4.3  11% and
.6  8% in overlap versus nonoverlap DES (p  NS), respectively. There were no differences in the
ates of uncovered/malapposed struts between overlapping BMS and DES, likely due to low fre-
uency of uncovered/malapposed struts in ZES (0.1  0.4%), which offset the higher rates observed
n SES (6.7  9.6%) and PES (6.7  16.5%, p  0.05). Overlap segments showed greater neointimal
olume obstruction versus nonoverlap segments in all DES (p  0.05 for all DES types). Strut-level
eointimal thickness at overlap and nonoverlap segments were lowest in SES (0.16  0.1 mm and
.12  0.1 mm, respectively) compared with PES (0.27  0.1 mm and 0.20  0.1 mm, respectively),
ES (0.40  0.16 mm and 0.33  0.13 mm, respectively), and BMS (0.55  0.31 mm and 0.53 
.25 mm, respectively, p  0.05).
onclusions As assessed by OCT the impact of DES on vascular healing was similar at overlapping
nd nonoverlapping sites. However, strut malapposition, coverage pattern, and neointimal hyperpla-
ia differ signiﬁcantly according to DES type. (Optical Coherence Tomography for Drug Eluting Stent
afety [ODESSA]; NCT00693030) (J Am Coll Cardiol Intv 2010;3:531–9) © 2010 by the American
ollege of Cardiology Foundation
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532rug-eluting stents (DES) are used with increasing frequency
n complex lesions and patients. However, blocking cellular
roliferation is not without consequences, and higher incidence
f late stent thrombosis (LST) has been associated with DES
ompared with bare-metal stents (BMS) (1). Postmortem
tudies have identified uncovered struts as the most powerful
athologic risk factor for LST (2). Moreover, DES have been
ssociated with higher incidence of malapposition or incom-
lete apposition, also predictors of LST (3,4).
Patients with long coronary lesions often require multiple
ES in overlap and might be at higher risk of stent
hrombosis, because double layers of DES might expose the
essel wall to higher and potentially toxic doses of drug and
olymer and alter flow (5). The impairment of arterial
ealing observed at overlapping DES in nonatherosclerotic
reclinical animal models supports this hypothesis (6), but
ittle is known about the local in vivo vascular effects of
overlapping DES in humans.
Optical coherence tomography
(OCT) can detect small degrees
of in-stent neointima more accu-
rately than intravascular ultra-
sound (IVUS) (7,8) and enables
detailed strut-level analysis of tis-
sue coverage and apposition in
humans (9). We planned a ran-
domized clinical trial with OCT
to investigate stent coverage and
apposition 6 months after deploy-
ment of overlapping DES or
BMS.
Methods
Design, patients, and procedures.
The ODESSA (Optical Coher-
ence Tomography for Drug-
luting Stent Safety) trial was a single-center randomized
pen-label trial with independent core laboratory imaging
nalyses (University Hospitals Cleveland Core Laboratory).
he study protocol was approved by the Ethics Committee,
nd all patients provided written informed consent.
Eligible subjects were older than 18 years of age, with
table or unstable coronary syndromes, long stenosis (20
m) in native coronary arteries, 2.5 to 3.5 mm in diameter,
equiring percutaneous coronary intervention (PCI) with
verlapping stents. Exclusion criteria were left main disease,
ngoing/recent myocardial infarction, previous target vessel
tenting, ejection fraction30%, creatinine2.5 mg/dl, no
uitable anatomy for OCT (ostial lesions and extreme
ortuosity), and inability to comply with dual antiplatelet
herapy and follow-up requirements.
Consecutive patients who signed informed consent were
bbreviations
nd Acronyms
MS  bare-metal stent(s)
ES  drug-eluting stent(s)
VUS  intravascular
ltrasound
ST  late stent thrombosis
IH  neointimal hyperplasia
CT  optical coherence
omography
ES  paclitaxel-eluting
tent(s)
ES  sirolimus-eluting
tent(s)
IT  strut-level intimal
hickness
ES  zotarolimus-eluting
tent(s):2:2:1 randomized to sirolimus-eluting stents (SES) gCypher, Cordis, Miami Lakes, Florida), paclitaxel-eluting
tents (PES) (Taxus Libertè, Boston Scientific, Natick,
assachusetts), zotarolimus-eluting stents (ZES) (En-
eavor, Medtronic, Santa Rosa, California) or BMS (Lib-
rtè, Boston Scientific). Only a single stent type was allowed
n each patient.
Coronary angioplasty was performed according to stan-
ard techniques. Direct stenting was allowed, and the
ecommended overlap length was 2 to 4 mm by visual
stimation. Glycoprotein IIb/IIIa inhibitors were at the
perator’s discretion. All patients were pretreated with
spirin 100 mg and clopidogrel 300 mg, followed by daily
dministration of clopidogrel 75 mg for at least 6 months
fter discharge plus aspirin. Patients were followed-up at 1
onth and 6 and 12 months after discharge by office visits
nd readmitted for planned follow-up angiography, IVUS,
nd OCT imaging at 6 months.
uantitative coronary angiography and IVUS. Digital angio-
rams were analyzed offline with CAAS II (PIE Medical,
aastricht, the Netherlands) (10). The stented segment
lus 5-mm distal and proximal edges were selected for
nalysis. Reference vessel diameter, minimum luminal di-
meter, percent diameter stenosis, and lesion length were
btained. Procedure success was defined as 10% residual
iameter stenosis with normal distal flow (Thrombolysis In
yocardial Infarction flow grade 3).
The IVUS was performed after injection of 200 g nitro-
lycerin after the procedure and at 6-month follow-up with
tlantis SR Pro 40 MHz and iLab (Boston Scientific).
maging included stents and the 5-mm stent edges with a 0.5
m/s pullback. All IVUS data were digitally stored and
ubsequently analyzed with Curad 4.32 (Curad, Wijkbij-
uurstede, the Netherlands) (11). Lumen and stent cross-
ectional areas were automatically measured, and neointimal
yperplasia (NIH) was calculated as the difference between
tent and lumen area (12).
CT. The OCT was conducted at 6-month follow-up, after
00 g intracoronary nitroglycerine. A time domain OCT
ystem (M2CV OCT Imaging System, LightLab Imaging,
estford, Massachusetts) was used. The occlusive tech-
ique was adopted to completely remove blood from the
rtery (9). Briefly, the occlusion balloon (Helios Goodman,
dvantec Vascular, Sunnyvale, California) compatible with
-F guiding catheters (0.071-inch inner diameter) was
dvanced distal to the stented segment over a conventional
ngioplasty guidewire. The guidewire was then replaced by
he 0.019-inch OCT ImageWire (LightLab Imaging). The
cclusion balloon was repositioned proximal to the stented
egment and inflated at low pressure (0.4 to 0.7 atm for a
aximum of 60 s; average 52.8  7.3 s), with simultaneous
nfusion of Ringer’s solution at 37°C with a flow rate of 0.5
o 1 ml/s through the distal tip of the catheter. Images were
cquired with an automated pullback at a rate of 1.0 mm/s,
enerating 15 frames/s (Fig. 1). Images were digitally stored
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533nd submitted to the core laboratory for offline evaluation
nd subsequent analysis.
Measurements of OCT cross-sectional images were per-
ormed with a dedicated, automated contour-detection
ystem (OCT system software B.0.1, LightLab Imaging)
eveloped in collaboration with the University Hospitals
maging core laboratory. All cross-sectional images (frames)
ere initially screened for quality assessment and excluded
rom analysis if any portion of the image was out of the
creen; a side branch occupied 45° of the cross-section; or
he image had poor quality caused by residual blood, sew-up
rtifact, or reverberation. Frames including the ostium of
ide branches were excluded from analysis. A strut was
onsidered suitable for analysis only if it had: 1) well-
efined, bright “blooming” appearance; and 2) characteristic
hadow perpendicular to the light source. Qualitative image
ssessment was performed in every frame (i.e., every 0.06
m), whereas quantitative measurements were performed
Figure 1. OCT 6-Month Follow-Up
Typical ﬁndings at intracoronary optical coherence tomography (OCT) 6 month
nal reconstruction. (B to E) The OCT sections in different segments (note over
Figure 2. Stent Struts Classification by Intracoronary OCT
Stent struts classiﬁcation by intracoronary optical coherence tomography (OCT
uncovered strut, and type IV–malapposed/uncovered strut. Reproduced with permissvery 5 frames (i.e., every 0.33 mm) along the entire stented
egment. In stented segments with multiple overlapping sites,
verlap segments were labeled in numerical order from distal to
roximal. The stented segment between 2 overlapping stents
as labeled as middle nonoverlapping segment. In addition,
CT data were computed for every 2.5-mm consecutive
egments, considering all the frames in this interval.
Strut-level qualitative OCT analysis was performed in
ach individual strut along the entire target segment. Struts
ere qualified in 4 categories: struts covered by tissue and
ot interfering with the lumen contour were defined as
non-protruding covered struts”; those interfering with the
umen contour were defined as “protruding covered struts”;
ncovered struts were defined as “protruding uncovered” or
malapposed struts” depending on quantitative measures as
escribed in the following text (Fig. 2).
The sharp contrast between lumen and vessel wall in
CT images allows fully automated delineation of the
r percutaneous coronary intervention with overlapping stents. (A) Longitudi-
g struts in D) showing heterogeneous strut coverage.
I/II–embedded strut, type IIIa–protuding/covered strut, type IIIb–protuding/s afte): type
ion from Guagliumi et al. (9).
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534umen contour. The inner and outer contours of each strut
eflection (blooming) were delineated semiautomatically.
he center of the luminal surface of the strut blooming was
etermined for each strut, and its distance to the lumen
ontour was calculated automatically to determine strut-
evel intimal thickness (SIT). Struts covered by tissue had
ositive SIT values, whereas protruding uncovered struts or
alapposed struts had negative SIT. Distance between
nner and outer strut reflection boundaries was measured in
,250 struts to determine strut blooming thickness, which is
ssential to properly determine malapposition as described
n the following text. Strut malapposition was determined
hen the negative value of SIT was higher than the sum of
trut thickness plus polymer thickness, according to the spec-
fications of each stent, corrected by strut blooming thickness,
hich was 37  8 m. To determine reproducibility of OCT
easurements, quantitative analyses in 333 struts were re-
Table 1. Baseline and Procedural Characteristics
SES
(n  22)
Age (yrs) 66.8 9.7
Male sex 15 (68.2)
Diabetes 8 (36.4)
Hypertension 11 (50.0)
Dyslipidemia 8 (36.4)
Prior myocardial infarction 10 (45.5)
Prior percutaneous coronary intervention 9 (40.9)
Multivessel coronary disease 19 (86.4)
Acute coronary syndrome at admission 10 (45.5)
Target vessel
Left anterior descending 13 (59.1)
Left circumﬂex 2 (9.1)
Right coronary artery 7 (31.8)
Stent/patient 2.5 0.5
Total stent length (mm) 55.5 15.9
Multiple overlapping stenting 10 (45.5)
Direct stenting 4 (18.2)
Post-dilation 14 (63.6)
Max inﬂation pressure (atm) 18.5 2.0
Values are expressed as mean SD or n (%).
BMS bare-metal stent(s); PES paclitaxel-eluting stent(s); SES sirolimus-eluting stent(s); ZE
Table 2. Optical Coherence Tomography Comparing Stent Types
SES
(64 Segments)
PES
(66 Segm
Volume obstruction 14.14 12.23 25.13
12.72 (4.01 to 44.04) 24.16 (5.66 t
Uncovered/malapposed struts 8.08 11.19 4.05
Malapposed struts 2.27 5.31 2.32
Covered struts 92.48 10.90 96.55
Values are given as percentages, but reported as mean SD, followed by median (5th to 95th percAbbreviations as in Table 1.eated by 2 independent analysts and repeated 3 months after
he initial analysis. The difference in stent area measurements
etween 2 analysts was 0.01  0.04%, whereas absolute
ifference in SIT was 0.01  0.02 m (R  0.997).
tudy end points. The primary end point was the proportion
f uncovered or malapposed struts in overlap versus nonoverlap
egments in DES and BMS, as defined by OCT analysis.
econdary imaging end points included percentage of uncov-
red or malapposed struts in SES, PES, and ZES; percentage
f NIH volume by IVUS; and late lumen loss by angiography
t overlapping versus nonoverlapping sites in DES versus
MS. Secondary clinical end points included 12-month major
dverse cardiac event rates, including death, myocardial infarc-
ion, and target vessel revascularization, as well as target lesion
evascularization and Academic Research Consortium-defined
tent thrombosis (13). All clinical events were adjudicated by
n external independent clinical event committee.
S
22)
ZES
(n  22)
BMS
(n  11) p Value
8.6 64.1 9.7 70.6 10.6 0.345
1.8) 15 (68.2) 9 (81.8) 0.610
8.2) 11 (50.0) 2 (18.2) 0.098
0.0) 11 (50.0) 4 (36.4) 0.873
0.0) 14 (63.6) 3 (27.3) 0.155
2.7) 7 (31.8) 3 (27.3) 0.426
6.4) 5 (22.7) 1 (9.1) 0.210
1.8) 20 (90.9) 9 (81.8) 0.516
0.0) 12 (54.5) 7 (63.6) 0.785
0.105
3.6) 17 (77.3) 3 (27.3)
3.6) 1 (4.5) 4 (36.4)
2.7) 4 (18.2) 4 (36.4)
0.5 2.5 0.7 2.4 0.5 0.926
13.8 51.4 15.1 53.8 19.1 0.127
6.4) 8 (36.4) 4 (36.4) 0.773
1.8) 4 (18.2) 4 (36.4) 0.491
2.9) 11 (50.0) 7 (63.6) 0.489
2.1 18.3 2.3 18.6 3.6 0.741
arolimus-eluting stent(s).
ZES
(74 Segments)
BMS
(35 Segments) p Value
40.17 14.07 53.85 21.58 0.001
2) 38.24 (15.18 to 66.50) 54.85 (21.58 to 86.27) 0.001
0.06 0.24 0.86 2.89 0.001
0.01 0.11 0.12 0.70 0.001
99.96 0.22 99.14 2.89 0.001PE
(n 
66.5
18 (8
4 (1
11 (5
11 (5
5 (2
8 (3
18 (8
11 (5
14 (6
3 (1
5 (2
2.4
44.6
8 (3
7 (3
9 (4
17.8ents)
13.31
o 47.7
10.26
9.31
8.67
entile).
S
l
p
n
a
g
o
d
7
m
e
c
a
c
s
c
(
s
e
p
C
l
t
R
B
i
c
S
2
s
p
(
O
c
w
f
w
t
a
s
a
t
[
t
o
t
N
p
(
(
ab
le
3
.
O
pt
ic
al
C
oh
er
en
ce
To
m
og
ra
ph
y
C
om
pa
ri
ng
O
ve
rl
ap
V
er
su
s
N
on
ov
er
la
p
S
eg
m
en
ts
by
S
te
nt
Ty
pe
S
ES
O
ve
rl
ap
(2
3
S
eg
m
en
ts
)
S
ES
N
on
ov
er
la
p
(4
1
S
eg
m
en
ts
)
P
ES
O
ve
rl
ap
(2
2
S
eg
m
en
ts
)
P
ES
N
on
ov
er
la
p
(4
4
S
eg
m
en
ts
)
Z
ES
O
ve
rl
ap
(2
6
S
eg
m
en
ts
)
Z
ES
N
on
ov
er
la
p
(4
8
S
eg
m
en
ts
)
B
M
S
O
ve
rl
ap
(1
1
S
eg
m
en
ts
)
B
M
S
N
on
ov
er
la
p
(2
4
S
eg
m
en
ts
)
na
ly
ze
d
st
ru
ts
/s
eg
m
en
t
11
0.
0

93
.2
*†
23
9.
5

14
9.
2*
†
12
2.
7

78
.2
*†
20
9.
3

10
5.
2*
†
19
4.
9

12
7.
4*
‡§

34
2.
2

16
4.
4*
‡§

10
6.
9

83
.6
*†
25
4.
9

14
3.
6*
†
tr
ut
-le
ve
l
ne
oi
nt
im
al
th
ic
kn
es
s
(m
m
)
0.
16

0.
1†
§
0.
12

0.
07
†§

0.
27

0.
11
*†
‡
0.
20

0.
1*
†‡

0.
40

0.
16
*‡
§
0.
33

0.
13
*‡
§
0.
55

0.
31
‡
0.
53

0.
25
†‡
§
IH
vo
lu
m
e
ob
st
ru
ct
io
n
19
.3
5

14
.1
*†
§
11
.2
1

10
.0
9*
†§

31
.5
7

14
.3
*†
‡
21
.9
2

11
.6
6*
†‡

45
.2
2

16
.0
1*
‡§
37
.4
4

12
.2
2*
‡§

57
.8
2

25
.2
4‡
52
.0
2

20
.0
3†
‡§
nc
ov
er
ed
/m
al
ap
p
os
ed
st
ru
ts
6.
71

9.
61
†
8.
85

12
.0
2†
§
6.
72

16
.5
2†
2.
71

4.
5†
‡
0.
10

0.
37
‡§
0.
02

0.
11
‡§
1.
52

3.
39
0.
56

2.
66
‡§
al
ap
p
os
ed
st
ru
ts
2.
93

6.
95
†
1.
90

4.
18
†
5.
51

15
.6
0†
0.
73

2.
12
†
0.
04

0.
18
‡§
0.
01

0.
01
‡§
0.
01

0.
01
0.
17

0.
85
‡§
ov
er
ed
st
ru
ts
94
.6
2

8.
19
†
91
.2
8

12
.0
9†
§
95
.0
8

13
.7
1†
97
.2
9

4.
50
†‡

99
.9
4

0.
33
‡§
99
.9
7

0.
11
‡§
98
.4
8

3.
39
99
.4
4

2.
66
‡§
al
u
es
ar
e
g
iv
en
as
p
er
ce
n
ta
g
es
u
n
le
ss
o
th
er
w
is
e
sp
ec
ifi
ed
,b
u
t
re
p
o
rt
ed
as
m
ea
n

SD
,f
o
llo
w
ed
b
y
m
ed
ia
n
(5
th
to
95
th
p
er
ce
n
ti
le
).
*p

0.
05
ve
rs
u
s
n
o
n
o
ve
rl
ap
se
g
m
en
t
w
it
h
in
th
e
sa
m
e
st
en
t
ty
p
e
g
ro
u
p
;†
p

0.
05
ve
rs
u
s
co
rr
es
p
o
n
d
in
g
se
g
m
en
t
o
fZ
ES
g
ro
u
p
;
p

0.
05
ve
rs
u
s
co
rr
es
p
o
n
d
in
g
se
g
m
en
t
o
fS
ES
g
ro
u
p
;§
p

0.
05
ve
rs
u
s
co
rr
es
p
o
n
d
in
g
se
g
m
en
t
o
fP
ES
g
ro
u
p
;
p

0.
05
ve
rs
u
s
co
rr
es
p
o
n
d
in
g
se
g
m
en
t
o
fB
M
S
g
ro
u
p
.
N
IH

n
eo
in
ti
m
al
h
yp
er
p
la
si
a;
o
th
er
ab
b
re
vi
at
io
n
s
as
in
Ta
b
le
1.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 5 , 2 0 1 0 Guagliumi et al.
MA Y 2 0 1 0 : 5 3 1 – 9 The ODESSA Trial
535tatistical analysis. Sample size was estimated from unpub-
ished data, assuming a difference of 1.0% in the segment
revalence of uncovered/malapposed struts in overlap versus
onoverlap segments in each stent group, an SD of 1.0%,
nd aiming for 1% alpha and 10% beta when comparing 2
roups at a time (yielding 15 patients/group). After accrual
f an additional 16 patients to take into account potential
eviations from normality and losses to 6-month follow-up,
6 patients were necessary.
Continuous variables are expressed as mean  SD or
edian (5th to 95th percentile), and categorical variables are
xpressed as n (%). For per-patient and per-lesion analyses,
ontinuous variables were compared with analysis of vari-
nce and Gosset t tests, and categorical variables were
ompared with chi-square or Fisher’s exact test. For per-
egment or per-strut analyses, continuous variables were
ompared with a complex samples general linear model
CSGLM), depending on cluster features. Given the highly
kewed distributions, all analyses for primary and secondary
nd points were confirmed with nonparametric tests. Com-
utations were performed with SPSS version 16.0 (SPSS,
hicago, Illinois), with statistical significance set at the 0.05
evel, and p values unadjusted for multiplicity are reported
hroughout.
esults
aseline and procedural data. A total of 77 patients were
ncluded in the study, with similar baseline and procedural
haracteristics (Table 1). Group allocations were as follows:
ES (n  22, 2.5  0.5 stent/patient ratio), PES (n  22,
.4  0.5 stent/patient ratio), ZES (n  22, 2.5  0.7
tent/patient ratio), and BMS (n  11, 2.4  0.5 stent/
atient ratio), with 3 stents deployed in 30 lesions
38.9%).
CT. The OCT imaging at follow-up was performed suc-
essfully in 75 eligible patients, because 1 patient died
ithin 30-days after procedure, and 1 patient was excluded
rom analysis because of protocol violation (a covered stent
as deployed in the target lesion due to a perforation during
he index procedure). There were no adverse events associ-
ted with the OCT imaging procedures.
A total of 53,047 struts in 6,968 cross-sections of 250
tented segments were analyzed (with 10 segments unsuit-
ble for analysis, and 40 segments of suboptimal quality due
o: vessel contour out-of-screen [n  16], side branches
n 16], and artifacts [n 8]). The primary end point (i.e.,
he rate of uncovered or malapposed struts) was similar in
verlap versus nonoverlap segments, irrespective of stent
ype (p  0.05 for any stent type) (Tables 2 and 3).
evertheless, higher overall rates of uncovered or malap-
osed struts were observed in SES (8.1  11.2%) and PES
4.05  10.3%) stented segments in comparison with ZES
0.06  0.24%) and BMS (0.86  2.9%, p  0.001), which T A S
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536as driven mainly by differences in nonoverlap segments.
ccordingly, the rate of uncovered/malapposed struts in
onoverlapping segments was 3.7  8.0% for the whole
ES group versus 0.6  2.7% for BMS (p  0.002).
Arterial response was heterogeneous among different
ES platforms (Tables 2 and 3, Fig. 3). The SES had
omogenously high rates of uncovered and malapposed
truts in overlap and nonoverlap segments. The PES
howed a trend of higher rates of uncovered and malap-
osed struts in the overlap segment. Notably, the ZES
xhibited homogenous and almost complete strut cover-
ge. The longitudinal distribution of uncovered and
alapposed struts along the entire stented vessel is shown
n Figure 3.
Percentage of volume obstruction was conversely higher
n overlap compared with nonoverlap segments in all DES
Tables 2 and 3, Fig. 4). Strut level intimal thickness was
ignificantly different across the different stent types.
uantitative coronary angiography, IVUS, and clinical data.
uantitative coronary angiography and IVUS data are
eported in Table 4. Angiographic and IVUS effectiveness
Figure 3. Longitudinal Distribution of Uncovered and Malapposed Struts Al
Prevalence of uncovered/malapposed struts/2.5-mm segments (y-axis) accordin
uncovered/malapposed struts along each 2.5-mm segments. Colors represent
(PES), zotarolimus-eluting stents (ZES), and bare-metal stents (BMS). Dist  dis
overlaps; OL1  distal overlap in patients with multiple overlaps or single ove
stented segment.arameters (i.e., late lumen loss, binary angiographic reste-
osis, NIH volume, and % NIH obstruction) were concor-
ant with OCT findings, showing SES to have the lowest
roliferative response compared with other stent types.
tent malapposition was noted by IVUS after procedure in
SES, 9 PES, 6 ZES, and 3 BMS only at nonoverlap
egments (p  NS). At follow-up only SES and PES had
ewly acquired stent malapposition in nonoverlap (SES
1.54% and PES 1.92%) and overlap segments (SES
2.9%).
The 12-month rates of death, myocardial infarction, or
arget vessel revascularization were not significantly different
cross the groups (p  0.097) (Table 5). There was 1 case
djudicated as probable subacute stent thrombosis in the
ES group, and no late stent thromboses.
iscussion
he present study establishes the feasibility and safety of
sing OCT to evaluate stent strut coverage and malap-
osition in a prospective, randomized, and controlled
e Stented Segments
ocation along the stented segment (x-axis). Bullet markers represent rate of
ual stented segments. Sirolimus-eluting stents (SES), paclitaxel-eluting stent
nted segment; Mid  segment between 2 overlaps in patients with multiple
L2  proximal overlap in patients with multiple overlaps; Prox  proximalong th
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537linical trial. The OCT showed increased NIH at the
verlap compared with nonoverlap stent segments, sug-
esting reduced efficacy at the site of overlapping DES.
onversely, similar rates of uncovered and malapposed
truts were observed between overlap and nonoverlap
ES, suggesting the safety of overlapping DES in
Figure 4. Rates of Uncovered and Malapposed Struts According to the
Stent Type and Location
Aggregate prevalence of 2.5-mm segments with 10%, 20%, and 30%
rates of uncovered and malapposed struts according to the stent type and
location. p  NS for comparisons between overlap (OL) versus nonoverlap
(Non-OL) within each group; †p  0.05 for the comparison between
groups in OL segments; ‡p  0.05 for the comparison between groups in
non-OL segment. Abbreviations as in Figure 3.
Table 4. Quantitative Coronary Angiography and IVUS
SES
(n  18)
Quantitative coronary angiography ﬁndings*
Baseline
Reference vessel diameter (mm) 2.89 0.61
Minimum lumen diameter (mm) 0.58 0.60
Diameter stenosis 80.3 18.5
Lesion length (mm) 36.7 12.2
Post-procedure (in-segment)
Minimum lumen diameter (mm) 1.79 0.46
Diameter stenosis 27.1 10.1
6-month follow-up
Minimum lumen diameter (mm) 1.76 0.61
Diameter stenosis 30.8 18.6
Late lumen loss (mm) 0.04 0.43
Binary angiographic restenosis 2 (10.5%)
IVUS at 6 months
Neointimal hyperplasia volume obstruction 7.92 10.25
Overlapping stent length (mm) 3.61 1.80
Values are given as percentages, unless otherwise specified. *In-segment.IVUS intravascular ultrasound; other abbreviations as in Table 1.umans. The study also confirmed the efficacy of DES
with SES being superior to PES, and PES being
uperior to ZES) in suppressing NIH in long coronary
esions at the expense of an overall higher incidence of
ncovered or malapposed struts in SES and PES com-
ared with ZES and BMS.
The success of DES in preventing restenosis likely
ontributed to the recent expansion in PCI indications to
nclude complex coronary artery disease. Despite limited
cientific evidence, the treatment of long coronary stenoses
ith multiple overlapping DES has become routine practice
orldwide (14).
trut coverage/apposition in overlapping stents. His-
opathologic evaluations of DES have revealed a high
ncidence of uncovered struts (4,15), and suggested the ratio
f uncovered to total number of stent struts to be the best
orphometric predictor of LST (2). Previous IVUS studies
ave also suggested a role for stent malapposition in the
athogenesis of DES thrombosis (3), but limited image
esolution hampered clinical confirmation. The present
tudy used OCT to evaluate rate and distribution of in vivo
ncovered and malapposed struts.
Overlapping SES and PES were associated with poor
ndothelial coverage in some animal models (15). In the
resent study, vascular responses among DES platforms
ere highly heterogeneous. There was an overall higher
ncidence of uncovered or malapposed struts in SES and
ES, but this was not influenced by overlap. Uncovered or
alapposed struts were equally distributed between overlap
nd nonoverlap in the SES, ZES, and BMS platforms. The
ES
20)
ZES
(n  21)
BMS
(n  11) p Value
 0.46 2.71 0.55 2.90 0.47 0.647
 0.51 0.68 0.50 0.68 0.43 0.933
 23.8 75.4 17.0 76.8 13.9 0.752
 13.3 39.3 12.8 37.4 23.1 0.126
 0.42 1.74 0.27 1.89 0.42 0.683
 9.1 26.6 8.8 23.7 15.6 0.624
 0.34 1.51 0.54 1.25 0.63 0.059
 11.0 37.7 22.3 49.3 26.0 0.011
 0.29 0.25 0.51 0.65 0.61 0.010
.8%) 5 (23.8%) 5 (45.5%) 0.026
 11.56 32.20 15.64 47.91 18.76 0.001
 1.93 3.80 2.29 3.91 4.07 0.701P
(n 
2.70
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538elevance of the nonhomogeneous distribution of malap-
osed PES struts with numerically yet not statistically
ignificant higher incidence of malapposed struts at the site
f PES overlap compared with nonoverlap is unclear and
arrants further investigation.
The rates of uncovered or malapposed struts observed in
he present study are lower than previously suggested by
istopathology data, even after restructuring the data in
.5-mm segments (Fig. 3) to parallel histomorphometric
nalyses (2). The maximum rate of segments containing
30% uncovered struts was 10%, which was found in
onoverlapping SES segments. Differences in definitions
nd methodology might explain discrepancy between in vivo
nd postmortem studies (4,6). Of note, the previous histo-
athology study included a small number of highly selected
ostmortem samples, and the mean length of overlap in the
xperimental study was 9.8 mm, which does not correspond
o common clinical practice as performed in the present
tudy.
The increased rates of stent malapposition in the SES
roup demonstrated by IVUS are consistent with the OCT
ndings. Pooled data and retrospective analyses from pre-
ious studies have shown the early (1 year) safety of
verlapping PES and SES. Reconciliation of the present
CT findings with clinical data would require larger studies
ith serial OCT assessment and longer follow-up evalua-
ions, because the vascular responses depicted by OCT
ight have a delayed clinical appearance. At this early stage
f OCT clinical trials, no cause-effect relationship can be
stablished between OCT findings and clinical outcomes.
evertheless, the low frequency of uncovered or malapposed
truts in DES platforms, even in the SES, matches the
Table 5. Clinical Outcomes
SES
(n  22)
PE
(n 
In-hospital events
Procedural success 21 (95.5%) 21 (9
Death 0 0
Acute stent thrombosis 0 0
Cumulative events at 12 months
Major adverse cardiac events 4 (18.2%) 5 (2
Death 1 (4.5%) 1 (4
Myocardial infarction 2 (9.1%) 2 (9
Target vessel revascularization 1 (4.5%) 2 (9
Target lesion revascularization 1 (4.5%) 2 (9
Subacute stent thrombosis 1 (4.5%) 0
Deﬁnite 0 0
Probable 1 (4.5%) 0
Late stent thrombosis 0 0
Values are given as percentages, unless otherwise specified.
Abbreviations as in Table 1.eported low rates of very late clinical stent thrombosis. seointimal thickness in overlapping DES. The present study
sed OCT, in addition to IVUS and angiography, to
rovide a sensitive measure of neointimal thickness at the
trut level. Our findings suggested decreased efficacy at the
ite of overlap compared with nonoverlap DES segments.
his vascular response was noted even in the SES group.
he ZES and PES had an overall lower SIT compared with
MS, although NIH was similar in the overlap sites of these
ES platforms compared with BMS. Previous pre-clinical
xperiments have suggested increased neointimal thickness
n overlapping ZES compared with SES. Whether excessive
ascular injury caused during deployment or by a permanent
ual layer of struts—which are more rigid—are associated
ith these findings remains to be determined.
The findings of higher degrees of NIH and apparent
igher degrees of strut malapposition at the site of overlap
ES is somewhat novel and suggest that neointimal prolif-
ration does not always translate into strut coverage or
pposition. The OCT confirmed in vivo the heterogeneous
haracter of the arterial wall response to coronary stents,
ith the co-existence of completely embedded struts with
xuberant NIH and malapposed uncovered struts within a
ingle cross-sectional image. The variable coverage of stent
truts in DES might be related to the distinctive arterial
eaction produced by each specific stent type and heteroge-
eous characteristics of the atherosclerotic plaque.
tudy limitations. Drawbacks of this study include the
ingle-center design, selected population, and reliance on
urrogates. In addition, OCT cannot detect 20 m tissue
overage or differentiate between very small amounts of
hrombus or fibrin deposition or even inflammatory cellular
esponse from the underlying NIH. New OCT imaging
ZES
(n  22)
BMS
(n  11) p Values
21 (95.5%) 10 (90.9%) 0.941
0 0 1.0
0 0 1.0
4 (18.2%) 6 (54.5%) 0.097
0 0 0.673
1 (4.5%) 2 (18.2%) 0.648
3 (13.6%) 4 (36.4%) 0.072
3 (13.6%) 4 (36.4%) 0.072
0 0 0.469
0 0 1.0
0 0 0.469
0 0 1.0S
22)
5.5%)
2.7%)
.5%)
.1%)
.1%)
.1%)ystems based on frequency-domain or Fourier-domain
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539echnology will enable coronary imaging without need for
alloon occlusion. It is also possible that cross-sectional area
easurements would be different between occlusive versus
on-occlusive techniques, but it is unlikely that assessment
f stent coverage and neointimal thickness would be
ffected.
onclusions
he 6-month OCT revealed a similar impact of DES on
tent coverage at overlapping and nonoverlapping sites but
educed efficacy at overlap. In addition, OCT showed a
eterogeneous vascular response according to DES type,
ith higher rates of uncovered or malapposed struts in PES
nd SES compared with low rates observed in BMS and
ES.
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